Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

The headquarters of the U.S. Food and Drug Administration, in Silver Spring, Maryland.

Jason Reed/Reuters

Newly unearthed documents show that the U.S. Food and Drug Administration failed to use its policing powers to make sure a program to curb improper prescribing of opioids was effective, researchers say.

The lax oversight, they point out, occurred as the epidemic was growing and tens of thousands of people were dying from overdoses each year.

In 2011, the FDA began asking the makers of OxyContin and other addictive long-acting opioids to pay for safety training for more than half the physicians prescribing the drugs, and to track the effectiveness of the training and other measures in reducing addiction, overdoses and deaths.

Story continues below advertisement

But the FDA was never able to determine whether the program worked, researchers at Johns Hopkins Bloomberg School of Public Health found in a new review, because the manufacturers did not gather the right kind of data. Although the agency’s approval of OxyContin in 1995 has long come under fire, its efforts to ensure the safe use of opioids since then have not been scrutinized nearly as much.

The documents show that even when deficiencies in these efforts became obvious through the FDA’s own review process, the agency never insisted on improvements to the program, called a risk evaluation and mitigation strategy, or REMS. The new research was published Monday in JAMA Internal Medicine.

“What’s surprising here is the design of the program was deficient from the start,” said Caleb Alexander, the senior author of the study, who serves as a paid expert witness in litigation against opioid manufacturers and distributors. “It’s unclear why the FDA didn’t insist upon a more scientifically rigorous evaluation of this safety program.”

Andrew Kolodny, the co-director of opioid policy research at the Heller School for Social Policy and Management at Brandeis, said the safety program was a missed opportunity. He is a leader of a group of physicians who had encouraged the FDA to adopt stronger controls.

He called the program “a really good example of the way FDA has failed to regulate opioid manufacturers. If FDA had really been doing its job properly, I don’t believe we’d have an opioid crisis today.”

In 2007, Congress gave the agency the authority to require drug manufacturers to train physicians to safely prescribe certain dangerous drugs and to monitor the companies’ performance. The bill, lawmakers said, was influenced by agency lapses in oversight of drugs such as Vioxx, a popular painkiller withdrawn from the market in 2004 after it was found to pose a substantial heart risk.

The main goals of the 2011 program for long-lasting opioids were to train more than half of an estimated 320,000 doctors who prescribed the drugs on how to do so safely and to inform patients about the significant risks of taking the drugs.

Story continues below advertisement

But Hopkins researchers, who relied on thousands of pages of internal FDA documents obtained through the Freedom of Information Act, found the agency repeatedly could not determine whether the companies’ safety strategies were working because of poor study designs, which the agency itself had approved.

Asked for a response, the FDA had no immediate comment.

There were early warning signs that the safety program for long-acting opioids had weaknesses. In 2010, an FDA advisory committee of experts in the treatment of pain voted 25-10 against the proposed program design. Committee members suggested that the agency require training for prescribers, and that it redesign curriculums to lessen industry influence. The FDA moved forward anyway.

A 2013 report by the inspector-general of the U.S. Department of Health and Human Services found that only 14 per cent of the safety programs reviewed by the FDA met their goals. And another inspector-general report last year noted that the agency did not have the authority to take enforcement actions against companies that don’t provide it with enough information to assess their safety programs – a common problem, it found.

“If FDA does not have comprehensive data to monitor the performance” of the program, the report said, “it cannot ensure that the public is provided maximum protection from a drug’s known or potential risks.”

In the case of long-acting opioids, the FDA wanted 60 per cent of prescribers to take the classes developed as part of the program. But only about 27 per cent did so within the specified time frame, 2012 to 2016. Surveys conducted by manufacturers found “modestly greater” knowledge of safe prescribing practices among doctors who took the classes than among those who did not. But opioid prescribing was dropping over all at that point, and the surveys were not designed in a way that could determine whether doctors who took the classes prescribed less as a result.

Perhaps most importantly, researchers found that manufacturers didn’t do a good job of assessing whether the safety program led to fewer overdoses and deaths. Instead, they relied on broad national data that made no distinction between patients of doctors who had taken the safety classes and those who had not – a problem the FDA pointed out repeatedly, in the third, fourth and fifth years of the program.

Last year, the same Hopkins researchers found failings in a similar safety program the FDA established in 2011 to curb inappropriate use of a small class of fast-acting fentanyl drugs meant only for cancer patients. The program required doctors who prescribed those drugs to take classes and sign forms saying they understood the dangers of prescribing to patients who did not have cancer, but many continued prescribing the drugs much more widely.

Story continues below advertisement

The researchers also found that the FDA did nothing to sharpen the safety program for the drugs, known as transmucosal immediate release fentanyls, even though it was aware of the broader prescribing. Top executives of one manufacturer, Insys Therapeutics, were criminally convicted in May of bribing doctors to prescribe and give sham educational talks about its drug Subsys, and of misleading insurers about patients’ need for the drug.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies